Skip to content

Clinical trials

Neurofibroma, Plexiform trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Neurofibroma, Plexiform Country / region: United States Clear all

43 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20013
20022
20042
20062
20082
20112
20121
20131
20141
20154
20162
20172
20183
20193
20212
20221
20231
20242
20253
20262

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed16
Active, not recruiting9
Recruiting8
Terminated4
Withdrawn2
Enrolling by invitation2
Available1
Approved for marketing1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Cancer Institute (NCI)17
Indiana University3
University of Alabama at Birmingham3
AstraZeneca2
Children's Hospital of Philadelphia2
Novartis Pharmaceuticals2
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany2
Alexion Pharmaceuticals, Inc.1
Ann & Robert H Lurie Children's Hospital of Chicago1
Children's National Research Institute1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Neurofibroma, Plexiform43
Neurofibromatosis 129
Neurofibroma8
Neurofibromatoses8
Neoplasms4
Neuroblastoma3
Neurofibrosarcoma3
Precancerous Conditions3
Brain Neoplasms2
Histiocytosis, Langerhans-Cell2

Trials

Showing 1 to 25 of 43. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.